Comments on current therapeutic possibilities for neovascular age-related macula degeneration

Klinische Monatsblätter für Augenheilkunde

Abstract

New treatments for neovascular age-related macular degeneration have emerged recently, and data from phase III clinical trials are now available. In the light of these data, expert guidance appears prudent to aid ophthalmologists to select the most appropriate therapeutic strategy for the individual patient. Therapeutic options discussed include laser photocoagulation, PDT with verteporfin, triamcinolone and its possible combination with PDT, anecortave acetate, pegaptanib and ranibizumab. Treatment principles are described and relevant clinical data summarized. Extrafoveal classic CNVs should be treated with thermal laser coagulation. For subfoveal lesions with predominantly classic CNV, or occult forms with non-classic CNV, a lesion size < or = 4 macular photocoagulation study (MPS) disc areas (DA) and recent disease progression, PDT with verteporfin is a safe and efficacious treatment. For the remaining subtypes, VEGF inhibitors (pegaptanib, ranibizumab, bevacizumab) for intravitreal use are now available as therapeutic alternatives. The results of the phase III studies for pegaptanib and ranibizumab, however, are not comparable, in particular with reference to the outcomes in the control groups. Since bevacizumab and ranibi...Continue Reading

Citations

Jan 9, 2013·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·J GibbertS Stock

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.